Icon

TASIGNA (nda022068)- (EQ 200MG BASE,EQ 150MG BASE,EQ 50MG BASE)

NILOTINIB HYDROCHLORIDE NOVARTIS
EQ 200MG BASE,EQ 150MG BASE,EQ 50MG BASE
Yes No
2032-Oct-07 2012-Oct-29
2014-Oct-29 None
None No
Tasigna is a kinase inhibitor indicated for the treatment of:  Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.  Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.  Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.
1 1 0
Total Other Developers 22
Drugs with Suitability No
EQ 200MG BASE ** ** - - -
EQ 150MG BASE ** ** - - -
EQ 50MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.